L-029

Lacosamide solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant^®

• Formule empirique (notation de Hill): C₁₃H₁₈N₂O₃
• Numéro CAS: 175481-36-4
• Poids moléculaire : 250.29
• Numéro MDL: MFCD08272557
• Code UNSPSC : 41116107
• ID de substance PubChem : 329817347
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: certified reference material
• Forme: liquid
• Caractéristiques: Snap-N-Spike^®/Snap-N-Shoot^®
• Conditionnement: ampule of 1 mL
• Fabricant/nom de marque: Cerilliant^®
• Concentration: 1.0 mg/mL in acetonitrile
• Technique(s): gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• Application(s): clinical testing
• Format: single component solution
• Température de stockage: −20°C
• Chaîne SMILES: CC(N[C@H](COC)C(NCC1=CC=CC=C1)=O)=O
• InChI: 1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
• Clé InChI: VPPJLAIAVCUEMN-GFCCVEGCSA-N
• Informations sur le gène: human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Description

Description générale

A Certified Spiking Solution^® suitable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, prescription monitoring or pharmaceutical research. Lacosamide is a new antiepileptic drug developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. The drug is marketed under the trade name Vimpat^®.

Application

• Lacosamide solution as a mass spectrometry standard: A recent development in analytical techniques features a UPLC-MS/MS method for determining lacosamide and its metabolites, essential for drug-drug interaction studies. This research underlines lacosamide′s role as a critical pharmaceutical research tool in the study of anti-epileptic drugs and their interactions (Chen et al., 2023).


• Lacosamide as an anticonvulsant in pharmacological research: Investigations on the effects of chronic lacosamide on ovarian tissue in rats highlight the broader physiological impacts of long-term anti-seizure medication use. Such studies are critical for assessing the reproductive safety of anticonvulsants, informing guidelines for their use in women of childbearing age (Kart et al., 2022).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Vimpat is a registered trademark of Harris FRC Corporation

Informations sur la sécurité

• Pictogrammes: GHS02,GHS07
• Mention d'avertissement: Danger
• Mentions de danger: H225,H302 + H312 + H332,H319
• Conseils de prudence: P210 - P280 - P301 + P312 - P303 + P361 + P353 - P304 + P340 + P312 - P305 + P351 + P338
• Classification des risques: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
• Code de la classe de stockage: 3 - Flammable liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): 35.6 °F - closed cup
• Point d'éclair (°C): 2 °C - closed cup